Author/Authors :
Maleki، Jafar نويسنده Department of Biochemistry, Iran University of Medical
Sciences, Tehran, IR Iran , , Nourbakhsh، Mitra نويسنده Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Nourbakhsh, Mitra , Shabani، Mohammad نويسنده Department of Neuroscience, Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran Shabani, Mohammad , Korani، Mohsen نويسنده Department of Biochemistry, Baqiyatallah University of
Medical Sciences, Tehran, IR Iran , , Nourazarian، Seyed Manuchehr نويسنده Department of Laboratory Sciences, Tabriz University of
Medical Sciences, Tabriz, IR Iran , , Ostadali Dahaghi، Mohammad Reza نويسنده Hematology-Oncology and Stem Cell Transplantation Research
Center, Shariati Hospital, Tehran University of Medical Sciences,
Tehran, IR Iran , , Moghadasi، Mohamad Hossein نويسنده Departement of Laboratory, Labafi Nedjad Hospital, Social
Security Organization, Tehran, IR Iran ,
Abstract :
Background: Experimental and epidemiological evidence supports a role for steroid hormones in the pathogenesis of ovarian cancer. Among steroid hormones, 17B-estradiol (E2) has the most potent effect on proliferation, apoptosis and metastasis.
Objectives: In the present study, we investigated the effect of E2 on production of ROS and NO in ovarian cancer cells.
Materials and Methods: Ovarian adenocarcinoma cell line (OVCAR-3) was cultured and treated with various concentrations of E2, antioxidants (N-acetyle cysteine and Ebselen) and ICI182780 as an estrogen receptor antagonist. MTT test was performed to evaluate cell viability. NO and ROS levels were measured by Griess and DCFH-DA methods, respectively.
Results: ROS levels as well as NO levels were increased in OVCAR-3 cells treated with E2. The increase in ROS production was in parallel with increased cell viability which indicates that estrogen-induced ROS can participate in cancer progression. ICI182780 abolished E2-induced ROS production. Progesterone was also effective in reducing ROS and NO generation.
Conclusions: NO and ROS are important molecules in signaling networks in cell. These molecules can be used as therapeutic targets for prevention and treatment of ovary cancer and other estrogen-induced malignancies.
